Visit COVID-19 resources

[Skip to Content]

Use of Avastin (bevacizumab) in age related macular degeneration

Dec 15
2014

Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no

  • 15 December 2014

Association of choroidal thickness with eye growth: a cross-sectional study of individuals between 4 and 23 years – (Eye 28, 1482 (December 2014))

Dec 11
2014

Association of choroidal thickness with eye growth: a cross-sectional study of individuals between 4 and 23 years Eye 28, 1482 (December 2014). doi:10.1038/eye.2014.227 Authors: M O Zengin, E Karahan, S Yilmaz, E Cinar, I Tuncer & C Kucukerdonmez

  • 11 December 2014

Variations in the cone packing density with eccentricity in emmetropes – (Eye 28, 1488 (December 2014))

Dec 11
2014

Variations in the cone packing density with eccentricity in emmetropes Eye 28, 1488 (December 2014). doi:10.1038/eye.2014.229 Authors: S Dabir, S Mangalesh, K A Kumar, M K Kummelil, A Sinha Roy & R Shetty

  • 11 December 2014

Evaluation of choroidal thickness using spectral-domain optical coherence tomography in migraine patients during acute migraine attacks: a comparative study – (Eye 28, 1477 (December 2014))

Dec 11
2014

Evaluation of choroidal thickness using spectral-domain optical coherence tomography in migraine patients during acute migraine attacks: a comparative study Eye 28, 1477 (December 2014). doi:10.1038/eye.2014.218 Authors: A Karalezli, C Simsek, G Celik & F C Eroglu

  • 11 December 2014

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome – (Eye 28, 1469 (December 2014))

Dec 11
2014

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome Eye 28, 1469 (December 2014). doi:10.1038/eye.2014.222 Authors: M Ho, E C F Lo, A L Young & D T L Liu

  • 11 December 2014